ArticlePLoS neglected tropical diseases2015
Trends of Mycobacterium bovis Isolation and First-Line Anti-tuberculosis Drug Susceptibility Profile: A Fifteen-Year Laboratory-Based Surveillance.
Article in PLoS neglected tropical diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- One Health and surveillance of zoonotic tuberculosis in selected low-income, middle-income and high-income countries: A systematic review.PLoS neglected tropical diseases · 2022Pooled it
- Global prevalence of Mycobacterium bovis infections among human tuberculosis cases: Systematic review and meta-analysis.Zoonoses and public health · 2021Pooled it
- Assessment of Cattle Owners' Knowledge, Attitudes and Practices Regarding Bovine Tuberculosis in the Eastern Cape Province, South Africa.Public health challenges · 2026Article
- Animals as overlooked victims and vectors of tuberculosis: review ofOne health advances · 2026Review
- Genomic epidemiology of theFrontiers in microbiology · 2026Article
- Investigation of potential relationship betweenmazEF3, relJK, and vapBC3 genes and antimicrobial resistance inMycobacterium bovis.BMC infectious diseases · 2025Article
- Distinct Clinical Features of Extrapulmonary and Disseminated Tuberculosis in HIV- and Non-HIV-Associated Immunosuppression: A Retrospective Cohort Study.Open forum infectious diseases · 2025Article
- Demixer: a probabilistic generative model to delineate different strains of a microbial species in a mixed infection sample.Bioinformatics (Oxford, England) · 2025Article
- Disseminated Pyrazinamide-Resistant Mycobacterium Bovis in an AIDS Patient: The Role of Molecular Diagnosis and Optimized Therapy.Infection and drug resistance · 2025Article
- Phylogenetically Informative Mutations in Drug Resistance Genes of Human-InfectingTransboundary and emerging diseases · 2024Article
- Isolation of multidrug-resistant (MDR) Mycobacterium bovis from a dog in Korea.The Journal of veterinary medical science · 2022Article
- Diversity ofInfection and drug resistance · 2022Article
- A case report of transmission and disease caused by Mycobacterium caprae and Mycobacterium bovis in Lima, Peru.BMC infectious diseases · 2021Article
- TB or not TB? Definitive determination of species within the Mycobacterium tuberculosis complex in unprocessed sputum from adults with presumed multidrug-resistant tuberculosis.Tropical medicine & international health : TM & IH · 2021Article
- Prevalence of latent tuberculosis in patients with hematological neoplasms in a cancer referral hospital in Mexico City.BMC infectious diseases · 2021Article
- Identification of drug resistance mutations among Mycobacterium bovis lineages in the Americas.PLoS neglected tropical diseases · 2021Article
- Risk practices for bovine tuberculosis transmission to cattle and livestock farming communities living at wildlife-livestock-human interface in northern KwaZulu Natal, South Africa.PLoS neglected tropical diseases · 2020Article
- Endogenous Tuberculous Endophthalmitis and Panophthalmitis: A Systematic Review of Case Reports and Case Series.Clinical ophthalmology (Auckland, N.Z.) · 2020Article
- Article
- Case report: systemic tuberculosis caused by Mycobacterium bovis in a cat.BMC veterinary research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMycobacterium tuberculosis causes the majority of tuberculosis (TB) cases in humans; however, in developing countries, human TB caused by M. bovis may be frequent but undetected. Human TB caused by M. bovis is considered a zoonosis; transmission is mainly through consumption of unpasteurized dairy products, and it is less frequently attributed to animal-to-human or human-to-human contact. We describe the trends of M. bovis isolation from human samples and first-line drug susceptibility during a 15-year period in a referral laboratory located in a tertiary care hospital in Mexico City. METHODOLOGY/PRINCIPAL
findingsData on mycobacterial isolates from human clinical samples were retrieved from the laboratory's database for the 2000-2014 period. Susceptibility to first-line drugs: rifampin, isoniazid, streptomycin (STR) and ethambutol was determined. We identified 1,165 isolates, 73.7% were M. tuberculosis and 26.2%, M. bovis. Among pulmonary samples, 16.6% were M. bovis. The proportion of M. bovis isolates significantly increased from 7.8% in 2000 to 28.4% in 2014 (X(2)trend, p<0.001). Primary STR resistance was higher among M. bovis compared with M. tuberculosis isolates (10.9% vs.3.4%, p<0.001). Secondary multidrug resistance (MDR) rates were 38.5% and 34.4% for M. bovis and M. tuberculosis, respectively (p = 0.637). A rising trend of primary STR monoresistance was observed for both species (3.4% in 2000-2004 vs. 7.6% in 2010-2014; p = 0.02). CONCLUSIONS/SIGNIFICANCE: There is a high prevalence and a rising trend of M. bovis isolates in our region. The proportion of pulmonary M. bovis isolates is higher than in previous reports. Additionally, we report high rates of primary anti-tuberculosis resistance and secondary MDR in both M. tuberculosis and M. bovis. This is one of the largest reports on drug susceptibility of M. bovis from human samples and shows a significant proportion of first-line anti-tuberculosis drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.